MGTX
HEALTHCAREMeiraGTx Holdings plc
$9.90+0.15 (+1.54%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MGTX Today?
No stock-specific AI insight has been generated for MGTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.55$11.85
$9.90
Fundamentals
Market Cap$916M
P/E Ratio—
EPS$-1.42
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume495K
Avg Volume (10D)—
Shares Outstanding92.6M
MGTX News
20 articles- Will Alector (ALEC) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 7, 2026
- Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?Yahoo Finance·May 7, 2026
- Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 5, 2026
- Miami International, Nathan’s Famous, and 3 More Stocks See Action From Activist InvestorsYahoo Finance·May 1, 2026
- Here is Why MeiraGTx Holdings (MGTX) is One of the Best Growth Stocks Under $10Yahoo Finance·Apr 25, 2026
- OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts AheadYahoo Finance·Apr 22, 2026
- MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 20, 2026
- Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector RevisionsYahoo Finance·Apr 17, 2026
- MeiraGTx Announces Pricing of $100 Million Offering of Ordinary SharesYahoo Finance·Apr 16, 2026
- MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)Yahoo Finance·Apr 16, 2026
- MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced XerostomiaYahoo Finance·Apr 16, 2026
- MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026Yahoo Finance·Apr 14, 2026
- Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?Yahoo Finance·Mar 31, 2026
- MeiraGTx Holdings plc (NASDAQ:MGTX) Just Reported And Analysts Have Been Cutting Their EstimatesYahoo Finance·Mar 30, 2026
- MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass EstimatesYahoo Finance·Mar 26, 2026
- MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational ResultsYahoo Finance·Mar 26, 2026
- MeiraGTx Highlights Late-Stage Gene Therapy Pipeline at RBC Ophthalmology ConferenceMarketbeat·Mar 26, 2026
- X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 17, 2026
- Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 9, 2026
All 20 articles loaded
Price Data
Open$9.89
Previous Close$9.75
Day High$10.13
Day Low$9.64
52 Week High$11.85
52 Week Low$4.55
52-Week Range
$4.55$11.85
$9.90
Fundamentals
Market Cap$916M
P/E Ratio—
EPS$-1.42
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume495K
Avg Volume (10D)—
Shares Outstanding92.6M
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—